Frequent and high-dose administration of interferon to patients with viral hepatitis results in various side effects. In our previous study, a novel liver-targeting interferon (IFN-CSP) combining Plasmodium region I peptide with IFN 2b was successfully designed and expressed in the Escherichia coli expression systems. This targeting would target the IFN 2b specifically to the liver, thus reducing the adverse events. In the present study, we further investigated the anti-HBV effects and molecular mechanisms of recombinant IFN-CSP in HepG2.2.15 cell line. Hepatitis B surface antigen (HBsAg) and HBe antigen (HBeAg) in the culture supernatants were analyzed by enzyme-linked immunosorbent assay (ELISA). HBV-DNA was measured by real-time quantitative PCR. HBV core protein was assayed by immunofluorescent and western blot analysis. The expressions of signal transducers and transactivator 1 (STAT1), STAT2, IFN regulatory factor 9 (IRF-9), and 2 -5 -oligoadenylate synthetase 1 (OAS1) were investigated by the reverse transcription PCR and western blot analysis. Results indicate IFN-CSP efficiently inhibited HBsAg and HBeAg secretion, HBV-DNA replication, and HBV core protein expression in HepG2.2.15 cells. The anti-HBV mechanisms involve activation of JAK-STAT signaling and increase of the anti-HBV protein OAS expression. IFN-CSP could be a good substitute for IFN 2b for anti-HBV treatment.
Introduction
Hepatitis B virus (HBV) is a DNA virus that spreads through infected blood or body secretions [1] . More than 400 million people are chronically infected with HBV worldwide [2, 3] . China has one of the largest HBV infected populations in the world [4] . HBV infection is directly related to the life expectancy due to acute, chronic hepatitis, cirrhosis and hepatocellular carcinoma (HCC) caused by HBV [5, 6] . Despite the availability of efficient vaccines, HBV infection remains a major global health concern.
The interferons (IFNs) are cytokines that exhibit antiviral, immunomodulatory, and antiproliferative activities [7] [8] [9] [10] . The biomedical interest in interferons is linked to their therapeutic efficacy against viral infections and cancer [11] . However, a variety of shortcomings have limited the widespread use of interferons, including the inability to obtain clinically relevant concentrations in vivo and limited access of exogenous interferons to the site of infection [12] . Novel strategy to enhance the in vivo efficacy of IFN by targeting it to specific site might circumvent these problems. Incorporation of Plasmodium region I peptide was demonstrated to be a promising strategy for the development of liver-targeting drug [13, 14] . In our previous study, a novel liver-targeting fusion interferon (IFN-CSP) combining Plasmodium region I peptide with IFN 2b was successfully designed and expressed in the Escherichia coli expression systems [15] . Liver tissue binding analysis revealed IFN-CSP specific targeting to liver tissue [15] . However, the anti-HBV effect of IFN-CSP still needs to be further studied and its precise molecular mechanism has not been identified.
To evaluate the anti-HBV effects and molecular mechanisms of recombinant IFN-CSP in vitro, HepG2.2.15 cell was used as in vitro model. Hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) in the culture supernatants were analyzed by enzyme-linked immunosorbent assay (ELISA). HBV-DNA was measured by real-time quantitative PCR. HBV core protein was assayed by immunofluorescent and western blot analysis. The expressions of signal transducers and transactivator 1 (STAT1), STAT2, IFN regulatory factor 9 (IRF9), and 2 -5 -oligoadenylate synthetase 1 (OAS1) were investigated by the reverse transcription-polymerase chain reaction (RT-PCR) and western blot analysis.
Materials and Methods

2.1.
Cell Culture and Materials. HepG2.2.15 cell, which has been stably transformed with two copies of the HBV genome into human hepatoblastoma cell line HepG2, was used as in vitro model to evaluate the anti-HBV effect and mechanism of IFN-CSP. The HepG2.2.15 cells were grown in complete DMEM (Gibco-BRL, CA) containing 10% FBS (Hyclone, Thermo Fisher, PA), 380 micro⋅g/mL G418 antibiotic (Sigma, MO), 100 units/mL penicillin, and 100 mg/mL streptomycin in a humidified incubator with 5% CO 2 at 37 ∘ C.
IFN 2b was purchased from Beijing Kaiyin Pharmaceutical Group (Beijing, China). IFN-CSP was expressed in Escherichia coli, with a specific activity of 1.2 × 10 8 IU/mg protein at a purity of over 95% [15] . 4 /well) with IFN 2b and various concentrations of IFN-CSP for 9 days. The culture medium was replaced every 3 days. The cells with media alone were used as controls. MTT solution (5 g/L) was added in the end of the incubation, and DMSO was added to solubilize the formazan. Optical density (OD) values were read at 570/630 nm. The survival ratio (%) was calculated using Survival rate (%) = ( OD sample OD control ) × 100%.
MTT Analysis for
2.3. Antiviral Experiments. Antiviral experiments were performed as previously described [16] . Briefly, the HepG2.2.15 cells were placed in 24-well plates (2 × 10 5 /well) and incubated for 24 h. Then, the culture medium was replaced by fresh medium with IFN 2b (at final a concentration of 10 3 IU/mL, = 3) or IFN-CSP (at final concentrations of 10 1 , 10 2 , and 10 3 IU/mL, = 3) for 9 days. The medium alone was added to the control wells ( = 3). The culture medium was replaced every 3 days. The cells were harvested for HBV core protein assays. The supernatants were harvested for HBV antigens and HBV-DNA assays.
To investigate the molecular mechanism of the anti-HBV effect of IFN-CSP, confluent HepG2.2.15 cells were pretreated for 1 h with 10 M of AG 490, a JAK inhibitor, and subsequently stimulated cells with either IFN-CSP or IFN 2b for 3 days [17] . The supernatants were harvested for HBV antigens and HBV-DNA assays. The cells were harvested for signal transducers and transactivator 1 (STAT1), STAT2, IFN regulatory factor 9 (IRF-9), and 2 -5 -oligoadenylate synthetase 1 (OAS1) mRNA and OAS1 protein assays. Images were captured using a confocal laser scanning microscope (TCS-NT, Leica Microsystems, Heidelberg, Germany). For western blot analysis, the treated cells were lysed in lysis buffer and cell lysates were separated in an SDS 12% polyacrylamide gel. The separated proteins were transferred to PVDF membrane and detected using primary polyclonal anti-HBcAg antibody (1 : 200; Abcam, England), anti-actin monoclonal antibody (1 : 1000; Santa Cruz Biotechnology, USA), and peroxidase-conjugated secondary antibodies followed by ECL detection. Immunoreactive bands were digitized using a scanner and signal was quantified using ImagePro Plus (IPP) software (Version 6.0, Media Cybernetics, USA). according to the manufacturer's instructions. The concentration and purity of total RNA were measured based on the A260 and A280 value and 1% agarose-formaldehyde gel electrophoresis. Synthesis of the complementary DNA was performed as described by the manufacturer using M-MLV reverse transcriptase (Promega, USA). PCR amplification was conducted on an ABI PRISM 7300 Sequence Detector System (Perkin-Elmer Applied Biosystems, CA) using PCR kit (Takara, China). The gene names, GenBank accession numbers, forward and reverse primer sequences, and product sizes are listed in Table 1 . Each reaction was performed in three replicate samples. The -actin gene was used as the standard. RT-PCR products were separated through 1.5% agarose gels. The signal was normalized by -actin and analyzed by Quantity One software (Bio-Rad, USA). OAS1 protein was measured and analyzed by a standard western blot procedure [18] using primary polyclonal anti-OAS1 antibody (1 : 200; Santa Cruz Biotechnology, USA), primary monoclonal anti-actin antibody, and peroxidaseconjugated secondary antibodies. The image was digitized using a scanner and signal was quantified using IPP software.
ELISA Analysis for
Statistical Analysis.
All data were expressed as the mean ± standard error of the mean (SEM). The homogeneity of variances was checked with Levene's test, and differences were analyzed by One-Way ANOVA using SPSS (version 13.0 for Windows) statistical software.
< 0.05 is considered statistically significant.
Results
Effect of IFN-CSP on HBV Antigens Secretion and HBV-DNA Replication.
The HBsAg and HBeAg in the supernatant of HepG2.2.15 cell culture system were determined by ELISA diagnostic kit. Treatment with IFN-CSP resulted in a significant reduction of HBsAg (Figure 1(b) ) and HBeAg (Figure 1(c) ) secretion in a dose-dependent manner. The secretions of HBsAg were significantly reduced, with inhibition ratios of 26.86, 38.92, and 66.01%, respectively. The inhibition ratio of IFN 2b on HBsAg was 64.83%. For HBeAg secretions, the inhibition ratios of IFN-CSP were 24.95, 37.40, and 53.53%, respectively. The inhibition ratio of IFN 2b on HBeAg was 51.30%. To further confirm the anti-HBV activity of IFN-CSP, the HBV-DNA levels in the culture supernatant were measured. The results revealed that the abundance of HBV-DNA (Figure 1(d) ) released into the culture medium was significantly decreased in a dose-dependently manner, with inhibition ratios of 27.82, 50.69, and 79.77%, respectively. The inhibition ratio of IFN 2b on HBV-DNA was 78.91%. IFN 2b and IFN-CSP at the concentration of tested (10 3 IU/mL) showed no cytotoxicity on the HepG2.2.15 cells, as analyzed by the MTT assay (Figure 1(a) ). (Figure 2(a) ) showed that the signal of HBV core protein is obviously decreased in the cytoplasm of HepG2.2.15 cells treated with IFN-CSP in a dose-dependent manner when compared with the control cells. IFN 2b control also suppress the expression of HBV core protein in HepG2.2.15 cells, but the suppress degree less than the same dose of IFN-CSP. The result of western blot (Figures 2(b) and 2(c)) was consistent with the immunofluorescent staining. Figure 1 , a clear increase in STAT1, STAT2, IRF-9, and OAS1 mRNA expressions was seen after stimulation with both IFN-CSP and IFN 2b (Figure 3) . We also observed a significant 
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Discussion
The present study demonstrates clearly that the novel liver targeting interferon IFN-CSP efficiently inhibited HBsAg and HBeAg secretion, HBV-DNA replication, and HBV core protein expression in HepG2. study also showed that IFN-CSP can act on HepG2.2.15 cells to induce the antiviral enzyme OAS1 through activating JAK-STAT signaling pathway. In our previous report, the IFN-CSP has been demonstrated that has liver-targeting potentiality [15] . Thus, it appears reasonable to speculate that IFN-CSP may accumulate in the liver tissue, improving the safety and efficacy of the therapeutic in comparison with free IFN 2b in vivo.
HBV marker is an indispensable tool for the evaluation of HBV infection, hepatitis, and cirrhosis caused by HBV.
Of the many different HBV markers used in clinical settings, HBsAg and HBeAg are effective serum markers for diagnosis of HBV infection and predicting flare-ups during therapy and determining when to conclude treatment [19] . The technique for measuring HBsAg and HBeAg levels is enzyme-linked immunosorbent assay. In the present study, the HepG2.2.15 cell line, containing multiple copies of the HBV (ayw subtype) genome that can stably secret HBV particles to supernatant, was used as in vitro model for identifying the secretion of HBV antigens [20] [21] [22] . The ELISA results showed that IFN-CSP significantly reduce the levels of HBsAg and HBeAg in the supernatant of HepG2.2.15 cells. HBV-DNA quantification is for diagnosis of breakthrough hepatitis via HBV mutation, evaluation of therapeutic effects, and assessment of liver disease [23] . High HBV-DNA levels also indicate a high risk of cancer. Since the results of immunofluorescent staining and western blot assay showed that IFN-CSP obviously decreased the level of cytoplasmic HBV core protein in HepG2.2.15 cells and a slightly better inhibit ability than native IFN 2b ( Figure 2 ). Moreover, it is critical to use concentrations that are not overtly cytotoxic since any impairment to cell functions would affect virus replication [24] . Our results showed that administration of the indicated concentration of IFN-CSP for 9 days did not induce cell death, indicating IFN-CSP achieved the anti-HBV effect without cytotoxicity on HepG2.2.15 cells.
The antiviral activities were dependent on IFN regulation of different signaling pathways. IFN stimulates a series of signal transduction events through binding of interferon to cell surface receptor. Among these pathways, the JAK-STAT signaling appeared to play a crucial role. The heteromeric IFN-stimulated gene factor 3 (ISGF3) complex, composed of STAT1, STAT2, and IRF-9, is a pivotal transcription factor in the JAK-STAT pathway [25] . In the study reported here, STAT1, STAT2, and IRF-9 mRNA levels in HepG2.2.15 cells treated with IFN-CSP 3 days were increased, consistent with the IFN 2b controls. This indicates IFN-CSP could also stimulate JAK-STAT signal transduction. OAS is considered to be the most sensitive biomarker of the effectiveness of IFN exposure, and it plays a critical role in mediating antiviral actions of interferon. In our experiments, a robust increase of the expressions of OAS1 mRNA and OAS1 protein by administration of IFN-CSP was similarly observed in HepG2.2.15 cells. The above information was further supported by the ability of a JAK inhibitor to attenuate the expression of STAT1, STAT2, IRF-9, and OAS1 induced by IFN-CSP. Moreover, impairment of JAK activity by the JAK inhibitor blockaded IFN-CSP induced anti-HBV effect in HepG2.2.15 cells. Thus, one of the possible mechanisms of the anti-HBV activity of IFN-CSP is activation of JAK-STAT signal transduction, followed by an increase in OAS.
In conclusion, we demonstrated that IFN-CSP efficiently inhibited HBsAg and HBeAg secretion, HBV-DNA replication, and HBV core protein expression in HepG2.2.15 cells. The anti-HBV mechanisms involve activation of JAK-STAT signaling and increase of the anti-HBV protein OAS expression. IFN-CSP could be a good substitute for IFN 2b for anti-HBV treatment.
